Pregabalin Efficacy in Treatment of Chronic Neurogenic Cough: A Comprehensive Clinical Review

MedXY Editorial Team•Jun 29, 2026•Clinical Updates

Pregabalin demonstrates significant efficacy in reducing symptoms of chronic neurogenic cough (CNC), with about 78% of patients reporting substantial improvement within approximately 6 weeks of treatment.
Significant reductions in validated patient-reported outcome measures, including HARQ and RSI scores, confirm the clinical benefit and moderate effect sizes of pregabalin therapy for CNC.
Response to pregabalin treatment is consistent regardless of patient sex or presence of gastrointestinal comorbidities such as hiatal hernia and reflux, highlighting its broad applicability.
Pregabalin is well tolerated, with only a small proportion of patients discontinuing therapy due to side effects.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Pregabalin demonstrates significant efficacy in reducing symptoms of chronic neurogenic cough (CNC), with about 78% of patients reporting substantial improvement within approximately 6 weeks of treatment.
Significant reductions in validated patient-reported outcome measures, including HARQ and RSI scores, confirm the clinical benefit and moderate effect sizes of pregabalin therapy for CNC.
Response to pregabalin treatment is consistent regardless of patient sex or presence of gastrointestinal comorbidities such as hiatal hernia and reflux, highlighting its broad applicability.
Pregabalin is well tolerated, with only a small proportion of patients discontinuing therapy due to side effects.